When is recombinant human parathyroid hormone (rhPTH, Natpara) indicated for treatment for chronic hypocalcemia?

Updated: Aug 08, 2019
  • Author: Manish Suneja, MD, FASN, FACP; Chief Editor: Vecihi Batuman, MD, FASN  more...
  • Print

Recombinant human parathyroid hormone (rhPTH, Natpara) is commercially available in the United States and is indicated as an adjunct to calcium and vitamin D to control hypocalcemia in patients with hypoparathyroidism. Its approval was based on the REPLACE trial, in which 48 of 90 patients (53%) receiving rhPTH, but only one of 44 patients in the placebo group (2%), achieved >50% reduction of daily PO calcium and vitamin D from baseline while maintaining serum calcium above baseline concentrations and less than upper limits of normal at week 24 (P< 0.0001). [48]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!